Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma

被引：0

作者：

Tan, Carlyn Rose ^{[1
]}

Maclachlan, Kylee ^{[2
]}

Nemirovsky, David ^{[3
]}

Derkach, Andriy ^{[1
]}

Hultcrantz, Malin ^{[2
]}

Hassoun, Hani ^{[2
]}

Mailankody, Sham ^{[2
]}

Shah, Urvi ^{[2
]}

Patel, Dhwani ^{[1
]}

Shekarkhand, Tala ^{[1
]}

Rueda, Colin ^{[1
]}

Lahoud, Oscar ^{[1
]}

Shah, Gunjan ^{[1
]}

Scordo, Michael ^{[1
]}

Chung, David ^{[4
]}

Landau, Heather ^{[4
]}

Giralt, Sergio ^{[1
]}

Usmani, Saad ^{[1
]}

Lesokhin, Alexander ^{[1
]}

Korde, Neha ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant & Cellular Therapy, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P166

引用

页码：S127 / S127

页数：1

共 50 条

[31] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, Jagoda K.
Kubicki, Tadeusz
Raje, Noopur
Vij, Ravi
Reece, Donna
Berdeja, Jesus
Derman, Benjamin A.
Rosenbaum, Cara A.
Richardson, Paul
Gurbuxani, Sandeep
Major, Sarah
Wolfe, Brittany
Stefka, Andrew T.
Stephens, Leonor
Tinari, Kathryn M.
Hycner, Tyler
Rojek, Alexandra E.
Dytfeld, Dominik
Griffith, Kent A.
Zimmerman, Todd M.
Jakubowiak, Andrzej J.
BLOOD, 2020, 136 (22) : 2513 - 2523
[32] Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
Tang, Wenjiao
Zhang, Li
Zheng, Yuhuan
Pan, Ling
Niu, Ting
FRONTIERS IN ONCOLOGY, 2024, 14
[33] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Korde, Neha
Derkach, Andriy
Hultcrantz, Malin
Maclachlan, Kylee H.
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Lesokhin, Alexander
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Hofmeister, Craig C.
Kaufman, Jonathan L.
Nooka, Ajay K.
Usmani, Saad Z.
Lonial, Sagar
Joseph, Nisha S.
BLOOD, 2023, 142
[34] Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial
Landgren, Ola
Hultcrantz, Malin
Diamond, Benjamin
Lesokhin, Alexander M.
Mailankody, Sham
Hassoun, Hani
Tan, Carlyn
Shah, Urvi A.
Lu, Sydney X.
Salcedo, Meghan
Werner, Kelly
Rispoli, Jenna
Caple, Julia
Sams, Allison
Verducci, Dennis
Jones, Katie
Concepcion, Isabel
Ciardello, Amanda
Chansakul, Aisara
Schlossman, Julia
Tavitian, Elizabet
Shekarkhand, Tala
Harrison, Angela
Piacentini, Casey
Rustad, Even H.
Yellapantula, Venkata
Maclaughlan, Kylee
Maura, Francesco
Landau, Heather J.
Scordo, Michael
Chung, David J.
Shah, Gunjan
Lahoud, Oscar B.
Thoren, Katie
Murata, Kazunori
Ramanathan, Lakshmi
Arcila, Maria E.
Ho, Caleb
Roshal, Mikhail
Dogan, Ahmet
Derkach, Andriy
Giralt, Sergio A.
Korde, Neha
JAMA ONCOLOGY, 2021, 7 (06) : 862 - 868
[35] Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos
A K Stewart
T Masszi
I Špička
A Oriol
R Hájek
L Rosiñol
D Siegel
G G Mihaylov
V Goranova-Marinova
P Rajnics
A Suvorov
R Niesvizky
A Jakubowiak
J San-Miguel
H Ludwig
S Ro
S Aggarwal
P Moreau
A Palumbo
Blood Cancer Journal, 2017, 7 : e554 - e554
[36] Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Mace, J. R.
Raje, N.
Attal, M.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Ahmadi, T.
Chiu, C.
Wang, J.
Van Rampelbergh, R.
Uhlar, C. M.
Kobos, R.
Qi, M.
Usmani, S. Z.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2104 - 2115
[37] Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Voorhees, Peter
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano
Anderson, Larry
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E353 - E354
[38] Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma
Kawano, Yawara
Hata, Hiroyuki
Takashio, Seiji
Tsujita, Kenichi
Ueda, Mitsuharu
Matsuoka, Masao
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E38 - E41
[39] Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma
Suzuki, Kazuhito
Gunji, Tadahiro
Kawashima, Masaharu
Uryu, Hideki
Nagao, Riku
Saito, Takeshi
Nishiwaki, Kaichi
Yano, Shingo
CANCERS, 2025, 17 (03)
[40] Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma
Gil-Fernandez, Juan Jose
Ramirez, Patricia Garcia
Charavia, Marta Callejas
CLINICAL CASE REPORTS, 2024, 12 (01):

← 1 2 3 4 5 →